Figure 2.

ISTF and anti-4-1BB mAb co-treatment induces marked expansion of CD11c⁺CD8⁺ T cells in splenocytes of tumor-bearing mice. Renca tumors were established and four groups of mice were treated with ISTF and/or anti-4-1BB mAb as described in Fig. 1. On day 14, splenocytes were excised; double stained with PE-, Cy- and FITC-conjugated antibodies and analyzed by fluorescence activated cell sorting. Bar charts indicating the proportions of (A) CD3⁺CD8⁺ T cells, (B) CD11c⁺CD8⁺ T cells, (C) CD4⁺Foxp3⁺ Treg cells, (D) CD11b⁺F480⁺ macrophages, (E) CD3⁺CD4⁺ T cells, (F) CD3⁺DX5⁺ natural killer cells, (G) CD11b⁺Gr1int⁺ myeloid cells and (H) B220⁺ B cells. Data are presented as the mean ± SD (n=3). *P<0.05 and **P<0.01. NS, not significant; ISTF, immunostimulatory factor; mAb, monoclonal antibody.